Short answer
Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Vir scheduled a November 9, 2026 investor call to disclose topline Phase 3 ECLIPSE 1 results in chronic hepatitis delta.
Vir Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Vir scheduled a November 9, 2026 investor call to disclose topline Phase 3 ECLIPSE 1 results in chronic hepatitis delta
- ECLIPSE 1 evaluates monthly subcutaneous elebsiran plus tobevibart, potentially supporting Vir’s lead CHD combination strategy
- Expanded Phase 2 SOLSTICE data include combination therapy and tobevibart monotherapy, providing additional efficacy and safety context
- Results webcast available through Vir’s investor website, with 30-day replay access
Item 8.01 · Other Events
- Phase 3 ECLIPSE 1 primary endpoint met: 44% achieved undetectable HDV RNA plus ALT normalization versus 0% delayed treatment, p<0.0001
- Key secondary endpoint: 79% achieved undetectable HDV RNA at Week 48 versus 0%, supporting broad antiviral efficacy
- HDV RNA became undetectable in 85% of cirrhotic patients and 73% of non-cirrhotic patients
- SOLSTICE Week 96: 100% of 28 patients completing combination therapy reached undetectable viremia
- Exploratory treatment-free data: 10 patients maintained SVR12 without viral rebound, but interim follow-up remains limited and incomplete
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vir Biotechnology, Inc. 8-K filings
Get the next VIR 8-K as it lands
Follow VIR for push alerts, or ask the research agent what this filing means.